FREE Online webinar organized by the EACTA Educational Committee and the Paediatric & Congenital Subcommittee
Click here to access the on-demand (available for EACTAIC members)
The
Early Extubation and Fast-Track Postoperative Care in Paediatric Congenital Cardiac Surgery, Rome, Italy, 29/03/2021-29/03/2021
has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with
2
European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Early extubation and fast-track postoperative care should be part of the programme in every institution where congenital cardiac surgery is performed. To do that of course a sustained enhanced recovery programme needs to be implemented by multidisciplinary team members who are experts in congenital heart disease and who are ready to make the next change.
After joining this webinar, you will better understand:
Paediatric cardiac surgeons, cardiovascular anaesthetists, perfusionists, paediatric intensivists, general anaesthetists, anaesthesia certified nurses, nurses, interns, and medical students.
Acknowledgement: photo in the banner is by Steffen Rex, MD, PhD
Have a look at the results of the poll submitted to the webinars’ participants. Do you agree with the results?
Mona Momeni
Belgium
| Time | Topic | Speaker |
|---|---|---|
| 17:00–17:10 | Introduction to the webinar | Mona Momeni, Belgium |
| 17:10–17:40 | What is the evidence for fast-track anaesthesia? | Joost van der Maaten, The Netherlands |
| 17:40–18:10 | How to implement a successful fast-track programme? | Susan C. Nicolson, Philadelphia, USA |
| 18:10–18:40 | Heart-lung interaction in congenital cardiac anaesthesia | Walid Habre, Switzerland |
| 18:40–19:10 | Dexmedetomidine: Usefulness for fast-track anaesthesia? | Steffen Rex, Belgium |
| 19:10–19:30 | Q&A from the audience | - |
The webinar is supported by an unrestricted educational grant by Livanova.
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively. For more information, please visit www.livanova.com